🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 42 of 857 · Phase 3 first, then by program name

  1. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  2. Carfilzomib

    Amgen

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  3. Cariprazine

    AbbVie

    Bipolar I Disorder

    phase 3 small molecule completed

    1 trial

  4. Cariprazine 0.5 mg capsules, hard, Reagila 6 mg hard capsules, Reagila 4.5 mg hard capsules, Reagila 3 mg hard capsules, Reagila 1.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent patient (13-17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  5. Carraguard (PC-515)

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule completed

    2 trials

  6. Carrellizumab + Capecitabine

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  7. Casdatifan

    Arcus Biosciences

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  8. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  9. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  10. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM, PLERIXAFOR

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  11. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, PLERIXAFOR, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  12. Casimersen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  13. Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat

    Lacuna Pharma Pty Ltd

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

  14. Casodex® 50 mg Film-coated Tablets, ANANDRON 150 mg, comprimé, Flutamide 250 mg Tablets, Xtandi - 40 mg soft capsules

    Ningbo Cancer Hospital

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  15. Cediranib

    AstraZeneca

    Recurrent Glioblastoma

    phase 3 small molecule completed

    1 trial

  16. Cediranib

    AstraZeneca

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  17. Ceftaroline

    Pfizer

    Community-Acquired Bacterial Pneumonia

    phase 3 small molecule completed

    1 trial

  18. Ceftazidime - Avibactam ( CAZ-AVI)

    Pfizer

    Complicated Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  19. Ceftazidime-avibactam

    Pfizer

    Complicated Intra-abdominal Infection

    phase 3 small molecule completed

    1 trial

  20. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial

  21. Celecoxib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  22. Celestone Cronodose suspensión inyectable, Ropivacaína Altan 7,5 mg/ml solución inyectable EFG, PLATELET CONCENTRATE

    The George Institute

    CHRONIC OMALGIA

    phase 3 small molecule active

    1 trial

  23. CellCept 500 mg film-coated tablets, CellCept 1 g/5 ml powder for oral suspension, Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 500 mg film-coated tablets

    Hoffmann-La Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

  24. Cellulose Sulfate gel (6%)

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources